Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

The epidermal growth factor receptor (EGFR) secondary kinase domain T790M non–small cell lung cancer (NSCLC) mutation enhances receptor catalytic activity and confers resistance to the reversible tyrosine kinase inhibitors gefitinib and erlotinib. Currently, irreversible inhibitors represent the pri...

詳細記述

保存先:
書誌詳細
主要な著者: Shimamura, Takeshi, Li, Danan, Ji, Hongbin, Haringsma, Henry J., Liniker, Elizabeth, Borgman, Christa L., Lowell, April M., Minami, Yuko, McNamara, Kate, Perera, Samanthi A., Zaghlul, Sara, Thomas, Roman K., Greulich, Heidi, Kobayashi, Susumu, Chirieac, Lucian R., Padera, Robert F., Kubo, Shigeto, Takahashi, Masaya, Tenen, Daniel G., Meyerson, Matthew, Wong, Kwok-Kin, Shapiro, Geoffrey I.
フォーマット: Artigo
言語:Inglês
出版事項: 2008
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272303/
https://ncbi.nlm.nih.gov/pubmed/18632637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-07-5428
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料